Management of Adverse Events for ALK-Targeted TKIs

A comprehensive review of key frontline trials for the treatment of ALK-rearranged non­–small cell lung cancer including, ALTA1, J-ALEX, and ALEX trials, as well as strategies for managing the different toxicity profiles of the ALK inhibitors.

For more resources and information regarding anticancer targeted therapies:

targeted oncology,oncology,cancer,